Form 4: Mineralys Therapeutics Director Daphne Karydas Reports Stock Option Award
SEC Form 4
Director Daphne Karydas reports acquisition of 22,000 stock options in Mineralys Therapeutics.
Summary
- Daphne Karydas, a director of Mineralys Therapeutics, Inc. (MLYS), filed a Form 4 on May 23, 2024, reporting a transaction that occurred on May 22, 2024.
- The transaction involved the acquisition of 22,000 stock options with an exercise price of $12.52.
- These options vest in 12 substantially equal monthly installments starting June 22, 2024, with a potential acceleration of vesting if the next annual meeting occurs before May 22, 2025.
- Following the reported transaction, Karydas directly owns 22,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It suggests confidence but doesn't provide concrete financial information.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of stock option grant. |
| 05/23/2024 | Date Form 4 was filed. |
| 06/22/2024 | Start date for monthly vesting of stock options. |
| 05/22/2025 | Potential date for accelerated vesting of stock options if annual meeting occurs before this date. |
| 05/22/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.